Danaher (NYSE: DHR) Q2 2026: EPS Beats, Guidance Raised, Bioprocessing Timing Weighs

Danaher Corporation (NYSE: DHR) reported second-quarter 2026 results on July 21, 2026, posting adjusted EPS of $1.94 against a consensus estimate of $1.85, a 4.7% positive surprise, while revenue rose 5.5% year-over-year to $6.3 billion. GAAP net income reached $870 million, or $1.23 per diluted share, a 60% increase year-over-year, reflecting the divergence between reported and adjusted figures driven largely by acquisition-related amortization.

Q2 2026 Results

• Adjusted EPS: $1.94, up 8.0% year-over-year from $1.80, beating the $1.85 consensus by 4.7%.
• GAAP EPS: $1.23 per diluted share, up 60% year-over-year, with GAAP net income of $870 million.
• Revenue: $6.3 billion, a 5.5% increase year-over-year; non-GAAP core revenue grew 3.0% year-over-year.
• Operating cash flow: $1.5 billion; non-GAAP free cash flow of $1.3 billion.
• Bioprocessing orders: grew mid-teens in the quarter, though customer project timing impacted revenue recognition in that segment.

What Drove the Results

Adjusted EPS of $1.94 beat the $1.85 consensus by $0.09, and revenue of $6.3 billion reflected a 5.5% year-over-year gain. Non-GAAP core revenue excluding respiratory testing grew 4.5% year-over-year, suggesting the underlying business expanded more broadly than the headline core figure implies. Life Sciences businesses delivered what the company described as their strongest quarter in several years, per CEO Rainer M. Blair's prepared remarks.

The primary area of investor focus was bioprocessing, where customer project timing weighed on revenue even as mid-teens order growth pointed to continued underlying demand. The gap between order trends and recognized revenue in bioprocessing appears to have contributed to the market's cautious reaction. Shares fell 10.99% on July 21, 2026, while the S&P 500 gained 0.83%.

The large spread between GAAP EPS of $1.23 and adjusted EPS of $1.94 reflects acquisition-related amortization, with the company disclosing estimated amortization of acquisition-related intangible assets of $1.9 billion for the full year 2026, including $0.5 billion expected in the third quarter alone. The earlier-than-anticipated completion of the Masimo Corporation acquisition contributed to this amortization load and also informed the company's decision to raise full-year guidance.

Outlook and Guidance

Danaher raised its full-year 2026 adjusted diluted EPS guidance to a range of $8.45 to $8.60, compared with prior guidance of $8.35 to $8.55. For the third quarter, the company expects non-GAAP core revenue to increase 2.0% to 3.0% year-over-year. Full-year 2026 non-GAAP core revenue is expected to grow 3.0% to 4.0% year-over-year. The company also cited an expectation to exit 2026 at a mid-single-digit core revenue growth rate. Foreign currency is estimated to reduce third-quarter sales by 1.0% and increase full-year sales by 0.5%, assuming exchange rates as of June 26, 2026.

Wall Street View

Analyst sentiment heading into the print was broadly constructive, with the majority of covering firms holding Buy or equivalent ratings. The raised guidance range provides a quantitative anchor for analysts reassessing price targets in the wake of the bioprocessing timing concerns and the sharp share decline.

Investor Takeaway

The mid-teens bioprocessing order growth is the most forward-looking data point in the quarter: if project timing normalizes in the second half, that order book supports accelerating revenue recognition into year-end. The Masimo acquisition integration timeline, reflected in $1.9 billion of annual amortization, will remain a recurring headwind to GAAP earnings comparisons, making the adjusted EPS trajectory the more meaningful near-term metric for tracking operational progress.